vs
Pacira BioSciences, Inc.（PCRX）与Shoals Technologies Group, Inc.（SHLS）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Shoals Technologies Group, Inc.的1.3倍（$177.4M vs $140.6M），Pacira BioSciences, Inc.净利率更高（1.6% vs -0.2%，领先1.9%），Shoals Technologies Group, Inc.同比增速更快（74.9% vs 5.0%），过去两年Shoals Technologies Group, Inc.的营收复合增速更高（19.0% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Shoals科技集团是可再生能源及电动出行领域的电气系统平衡解决方案供应商，核心产品覆盖光伏、储能及充电桩用连接组件，主要服务北美、欧洲、亚太市场的公用事业、工商业及民用客户。
PCRX vs SHLS — 直观对比
营收规模更大
PCRX
是对方的1.3倍
$140.6M
营收增速更快
SHLS
高出69.9%
5.0%
净利率更高
PCRX
高出1.9%
-0.2%
两年增速更快
SHLS
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $140.6M |
| 净利润 | $2.9M | $-297.0K |
| 毛利率 | — | 29.2% |
| 营业利润率 | 3.9% | 5.5% |
| 净利率 | 1.6% | -0.2% |
| 营收同比 | 5.0% | 74.9% |
| 净利润同比 | — | -5.3% |
| 每股收益（稀释后） | $0.07 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXSHLS
| Q1 26 | $177.4M | $140.6M | ||
| Q4 25 | $196.9M | $148.3M | ||
| Q3 25 | $179.5M | $135.8M | ||
| Q2 25 | $181.1M | $110.8M | ||
| Q1 25 | $168.9M | $80.4M | ||
| Q4 24 | $187.3M | $107.0M | ||
| Q3 24 | $168.6M | $102.2M | ||
| Q2 24 | $178.0M | $99.2M |
净利润PCRXSHLS
| Q1 26 | $2.9M | $-297.0K | ||
| Q4 25 | — | $8.1M | ||
| Q3 25 | $5.4M | $11.9M | ||
| Q2 25 | $-4.8M | $13.9M | ||
| Q1 25 | $4.8M | $-282.0K | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | $-143.5M | $-267.0K | ||
| Q2 24 | $18.9M | $11.8M |
毛利率PCRXSHLS
| Q1 26 | — | 29.2% | ||
| Q4 25 | 79.5% | 31.6% | ||
| Q3 25 | 80.9% | 37.0% | ||
| Q2 25 | 77.4% | 37.2% | ||
| Q1 25 | 79.7% | 35.0% | ||
| Q4 24 | 78.7% | 37.6% | ||
| Q3 24 | 76.9% | 24.8% | ||
| Q2 24 | 75.1% | 40.3% |
营业利润率PCRXSHLS
| Q1 26 | 3.9% | 5.5% | ||
| Q4 25 | 1.2% | 11.7% | ||
| Q3 25 | 3.5% | 13.7% | ||
| Q2 25 | 4.7% | 14.4% | ||
| Q1 25 | 1.2% | 5.4% | ||
| Q4 24 | 13.2% | 15.4% | ||
| Q3 24 | -82.8% | 4.4% | ||
| Q2 24 | 15.9% | 18.7% |
净利率PCRXSHLS
| Q1 26 | 1.6% | -0.2% | ||
| Q4 25 | — | 5.5% | ||
| Q3 25 | 3.0% | 8.7% | ||
| Q2 25 | -2.7% | 12.5% | ||
| Q1 25 | 2.8% | -0.4% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | -85.1% | -0.3% | ||
| Q2 24 | 10.6% | 11.9% |
每股收益（稀释后）PCRXSHLS
| Q1 26 | $0.07 | $0.00 | ||
| Q4 25 | $0.05 | $0.05 | ||
| Q3 25 | $0.12 | $0.07 | ||
| Q2 25 | $-0.11 | $0.08 | ||
| Q1 25 | $0.10 | $0.00 | ||
| Q4 24 | $0.38 | $0.04 | ||
| Q3 24 | $-3.11 | $0.00 | ||
| Q2 24 | $0.39 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $1.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $601.6M |
| 总资产 | $1.2B | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXSHLS
| Q1 26 | $144.3M | $1.9M | ||
| Q4 25 | $238.4M | $7.3M | ||
| Q3 25 | $246.3M | $8.6M | ||
| Q2 25 | $445.9M | $4.7M | ||
| Q1 25 | $493.6M | $35.6M | ||
| Q4 24 | $484.6M | $23.5M | ||
| Q3 24 | $453.8M | $11.1M | ||
| Q2 24 | $404.2M | $3.2M |
总债务PCRXSHLS
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | $141.8M | ||
| Q4 24 | $585.3M | $141.8M | ||
| Q3 24 | — | $141.8M | ||
| Q2 24 | — | $146.8M |
股东权益PCRXSHLS
| Q1 26 | $653.9M | $601.6M | ||
| Q4 25 | $693.1M | $600.0M | ||
| Q3 25 | $727.2M | $589.6M | ||
| Q2 25 | $757.8M | $575.4M | ||
| Q1 25 | $798.5M | $558.9M | ||
| Q4 24 | $778.3M | $556.8M | ||
| Q3 24 | $749.6M | $545.2M | ||
| Q2 24 | $879.3M | $544.6M |
总资产PCRXSHLS
| Q1 26 | $1.2B | $1.0B | ||
| Q4 25 | $1.3B | $904.1M | ||
| Q3 25 | $1.3B | $851.8M | ||
| Q2 25 | $1.5B | $795.0M | ||
| Q1 25 | $1.6B | $788.4M | ||
| Q4 24 | $1.6B | $793.1M | ||
| Q3 24 | $1.5B | $801.3M | ||
| Q2 24 | $1.6B | $788.4M |
负债/权益比PCRXSHLS
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | 0.25× | ||
| Q4 24 | 0.75× | 0.25× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 0.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SHLS
暂无分部数据
